<DOC>
	<DOCNO>NCT01593644</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerance dipyridamole/adenosine combination give intravenously , slow bolus low dos adenosine alone ( give recommend dosage adjust patient ' weight ) coronary flow reserve assessment ( 60-75 patient stable ischemic heart disease ) use transthoracic echodoppler</brief_summary>
	<brief_title>Phase II Study Diagnosis Functional Assessment CAD Using Transthoracic-Echodoppler</brief_title>
	<detailed_description>Phase 2 , monocentric , single blind study , compare efficacy ( primary endpoint ) safety-tolerance profile ( secondary endpoint ) dipyridamole/adenosine combination give intravenously slow bolus low dos adenosine alone give route standard recommend dose . Expected result : Non inferiority combination compare standard adenosine alone term hemodynamic efficacy , maintenance optimal hyperemic coronary effect least 45 60 second end injection -Significant reduction incidence rate A1 adverse event severity A2 A1 clinical symptom . Primary endpoint : diastolic mean peak coronary blood velocity Secondary endpoint : incidence rate severity adverse event , particular , chest pain , dyspnoea , hypotension , bradycardia , AV block , arrhythmia Number patient : 60-75 pt 42-50 pt acceptable statistical analysis Operating procedure : Day 1 ( visit ) : Informed consent signature , Review inclusion exclusion criterion , Hemodynamic variables EKG , Cardiac history , Significant medical disease , Risk factor , Concomitant treatment substance consume within 48 hour , Transthoracic ultrasonography , Adverse event report Day 2 ( telephone contact ) : Adverse event report Duration study : 15 month Statistical Analysis : Statistical test include : paired test analysis comparison mean ( quantitative variable ) -Possibly Mac-Nemar test assessment clinical adverse event study test product .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>Man postmenopausal woman oral contraceptive treatment , &gt; 18 year Provided write consent patient good understanding study objective explain investigator initial visit Patient potential know Coronary Artery Disease Patient transthoracic ultrasonography coronary reserve assessment deem useful Subjects 18 , pregnant breastfeed woman , psychotic patient subject place administrative legal authority Patients judge investigator able understand study objectives Patients medical history , particular heart disease history ( eg AV block ) judge non eligible investigator Patients whose medical treatment contra indicate inclusion study ( eg chronic use oral dipyridamole , pentoxifylline ) , stop least 72 hour study test Patients symptomatic bradycardia ( &lt; 40 beat/min ) systemic hypotension ( SBP &gt; 90 mmHg Patients 2nd 3rd degree AV block , sick sinus syndrome , artificial pacemaker Patients prolong QT ( QTc &gt; 480 m ) Patients oral dipyridamole stop medication 48hrs study test Patients receive theophylline within 5 day study test Consumption coffee , cola , tea , chocolate within 12 hr study test Patients history unstable Asthma Chronic Obstructive Pulmonary Disease bronchoconstriction Patients unstable angina pectoris uncontrolled severe heart failure Patients recent myocardial infarction history ( &lt; 7 day ) , stroke episode ( &lt; 1 month ) Patients known TC stenosis yet revascularized , uncontrolled hypovolemia , know unfixed valvular stenosis , leftright shunt , pericarditis , sympathetic nervous system dysfunction , carotid stenosis , significant cerebrovascular insufficiency Patients know allergy adenosine dipyridamole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Dipyridamole/adenosine combination give intravenously</keyword>
	<keyword>slow bolus low dos</keyword>
	<keyword>coronary flow reserve assessment</keyword>
	<keyword>transthoracic echodoppler</keyword>
	<keyword>Patients</keyword>
	<keyword>stable</keyword>
</DOC>